More on ARWR
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $67.74 |
|
|||
| Open | $67.74 | ||||
| 52 Wk High | $8.22 | ||||
| 52 Wk Low | $3.07 | ||||
| Day High | $67.74 | ||||
| Day Low | $67.74 | ||||
| P/E | N/A | ||||
| EPS | $-1.30 | ||||
| Volume | 2,354 | ||||
- Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA
- Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- Citi Starts Arrowhead Pharma (ARWR) at Buy
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
- Stifel Reiterates Buy Rating on Arrowhead Pharma (ARWR)
- RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
- Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data
- Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
- Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
- Form 4 ARROWHEAD PHARMACEUTICAL For: Aug 18 Filed by: OLUKOTUN ADEOYE Y
Entities mentioned with ARWR
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Show More...
